Kazia Therapeutics Limited filed a prospectus supplement on August 28, 2026, reducing the maximum aggregate offering price of American Depositary Shares under its March 17, 2026 Sales Agreement with Leerink Partners LLC from $100 million to $80 million. This adjustment modifies the existing registration statement on Form F-3 (File No. 333-294392). The company operates in the biotechnology industry, focusing on the development of therapeutic treatments for cancer.
